Browsing Tag
Hong Kong Stock Exchange
11 posts
Biocytogen just stacked two cancer bets in three days. Is its platform strategy starting to compound?
Biocytogen’s NEOK002 IND clearance and Moonlight Bio deal highlight a platform-led oncology strategy. Read what it means for growth and sentiment.
Insilico Medicine just doubled down on CNS with Tenacia. Here’s why that matters now.
Insilico Medicine has expanded its Tenacia CNS partnership in a deal worth up to $94.75 million. Read what it signals for AI drug discovery now.
Can Insilico Medicine’s PandaClaw agentic AI platform accelerate pharma software licensing revenue growth in 2026?
Insilico Medicine launches PandaClaw, an agentic AI tool that lets biologists run autonomous multi-omics drug discovery analysis. Read what it means for pharma.
Insilico Medicine, Hygtia Therapeutics to advance AI-designed NLRP3 inhibitor for CNS diseases
Insilico and Hygtia partner to advance ISM8969, a brain-penetrant AI-designed NLRP3 inhibitor for CNS diseases. Find out what this means for the field.
Ribo Life Science raises HKD1.8bn in Hong Kong IPO amid strong institutional support for siRNA growth strategy
Ribo Life Science’s HKEX IPO raised HKD 1.83B for siRNA drug development. See how it could reshape RNA biotech investment trends in Asia. Read more.
Innovent Biologics strengthens mazdutide’s global credibility as Phase 3 diabetes trials land in Nature
Innovent Biologics, Inc. lands back-to-back Nature Phase 3 wins for mazdutide in type 2 diabetes. See what it means for HKEX: 01801.
Pony.ai’s Gen-4 autonomous trucks are coming in 2026—can they redefine global freight logistics?
Pony.ai launches Gen-4 autonomous trucks and eyes global freight dominance following HK$7.7B dual IPO. Find out what this means for logistics in 2026.
HSBC’s $13.6bn Hang Seng Bank buyout: Why it’s betting big on Hong Kong’s financial future
HSBC is offering HK$106 billion to take Hang Seng Bank private. Find out why the lender is making this bold move and what it means for Hong Kong banking.
Xpeng stock jumps on European push — but can it deliver in a crowded market?
Discover how Xpeng is expanding aggressively in Europe — entering five new countries and launching localized EV production. See what this means for global EV competition.
Ascletis doses first obesity patients in U.S. Phase IIa trial of once-monthly GLP-1R depot ASC30
Ascletis (HKEX: 1672) begins dosing in U.S. Phase IIa obesity trial of ASC30, its once-monthly small molecule GLP-1R agonist, with topline data expected Q1 2026.